{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T12:54:17Z","timestamp":1791636857183,"version":"4.3.4"},"posted":{"date-parts":[[2026,9,24]]},"group-title":"Ophthalmology","reference-count":24,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.medrxiv.org\/about\/FAQ#license"}],"funder":[{"name":"National Institutes of Health","award":["R01EY028996"],"award-info":[{"award-number":["R01EY028996"]}]},{"name":"National Institutes of Health","award":["R44EY027632"],"award-info":[{"award-number":["R44EY027632"]}]},{"id":[{"id":"https:\/\/ror.org\/0269x8842","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,10,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>Frequent injections remain a substantial burden in the treatment of neovascular age-related macular degeneration (nAMD). AXT107 (gersizangitide) is a long-acting, integrin-disrupting peptide designed for suprachoroidal administration. In the phase 1\/2a, open-label DISCOVER trial, 15 participants with active nAMD received a single suprachoroidal injection of AXT107 microparticles at 0.125, 0.25, or 0.5 mg and were followed for 40 weeks. Safety and tolerability were the primary outcomes; visual acuity, retinal thickness, and time to protocol-specified rescue anti-vascular endothelial growth factor treatment were exploratory outcomes. No AXT107-related serious adverse events, clinically significant intraocular inflammation, or sustained intraocular pressure elevations were observed. Fourteen eyes met the protocol-specified baseline imaging criterion for efficacy analyses. Among these eyes, two treatment-experienced eyes completed 40 weeks without protocol-specified rescue, and a third first received protocol-specified rescue at week 36. Anatomical improvements were observed in at least one eye in each dose cohort, although responses varied. A single suprachoroidal injection of AXT107 was well tolerated in this small first-in-human study. The exploratory findings warrant evaluation in a controlled trial<\/jats:p>\n                <jats:sec>\n                  <jats:title>One Sentence Summary<\/jats:title>\n                  <jats:p>Suprachoroidal AXT107 was well tolerated, with some eyes remaining free of protocol-specified rescue for up to 40 weeks.<\/jats:p>\n                <\/jats:sec>","DOI":"10.64898\/2026.09.19.26363031","type":"posted-content","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:25:18Z","timestamp":1790285118000},"source":"Crossref","is-referenced-by-count":0,"title":["Single-Dose Suprachoroidal AXT107 in Neovascular Age-Related Macular Degeneration: The Phase 1\/2a DISCOVER Trial"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3652-0289","authenticated-orcid":false,"given":"Niranjan B.","family":"Pandey","sequence":"first","affiliation":[{"name":"Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, USA"},{"name":"AsclepiX Therapeutics, Inc., Bethesda, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0602-3011","authenticated-orcid":false,"given":"Adam C.","family":"Mirando","sequence":"additional","affiliation":[{"name":"Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, USA"},{"name":"AsclepiX Therapeutics, Inc., Bethesda, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7819-3397","authenticated-orcid":false,"given":"Thomas J.","family":"Robinson","sequence":"additional","affiliation":[{"name":"AsclepiX Therapeutics, Inc., Bethesda, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R. P.","family":"Almeida","sequence":"additional","affiliation":[{"name":"Eye Retina Research, Erie, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3444-8295","authenticated-orcid":false,"given":"Sabin","family":"Dang","sequence":"additional","affiliation":[{"name":"The Retina Institute, St. Louis, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Lally","sequence":"additional","affiliation":[{"name":"Retina Research Institute at New England Retina Consultants, Springfield, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"William Z.","family":"Bridges","sequence":"additional","affiliation":[{"name":"Asheville Eye Associates, PLLC, Asheville, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2531-8229","authenticated-orcid":false,"given":"Peter A.","family":"Campochiaro","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and The Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6706-9235","authenticated-orcid":false,"given":"Aleksander S.","family":"Popel","sequence":"additional","affiliation":[{"name":"Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4176-3808","authenticated-orcid":false,"given":"Jordan J.","family":"Green","sequence":"additional","affiliation":[{"name":"Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, USA"},{"name":"Department of Ophthalmology and The Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2026101005201191000_2026.09.19.26363031v2.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0801537"},{"key":"2026101005201191000_2026.09.19.26363031v2.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.09.006"},{"key":"2026101005201191000_2026.09.19.26363031v2.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa054481"},{"key":"2026101005201191000_2026.09.19.26363031v2.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2016.04.056"},{"key":"2026101005201191000_2026.09.19.26363031v2.5","doi-asserted-by":"crossref","unstructured":"P. A. Campochiaro , A. Akhlaq , Sustained suppression of VEGF for treatment of retinal\/choroidal vascular diseases. Prog. Retin. Eye Res. 83, 100921 (2021).","DOI":"10.1016\/j.preteyeres.2020.100921"},{"key":"2026101005201191000_2026.09.19.26363031v2.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.03.046"},{"key":"2026101005201191000_2026.09.19.26363031v2.7","first-page":"S172","article-title":"Review of neovascular age-related macular degeneration treatment options","volume":"25","year":"2019","journal-title":"Am. J. Manag. Care"},{"key":"2026101005201191000_2026.09.19.26363031v2.8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00010-1"},{"key":"2026101005201191000_2026.09.19.26363031v2.9","first-page":"S2","article-title":"Geographic atrophy: Mechanism of disease, pathophysiology, and role of the complement system","volume":"29","year":"2023","journal-title":"J. Manag. Care Spec. Pharm"},{"key":"2026101005201191000_2026.09.19.26363031v2.10","doi-asserted-by":"crossref","unstructured":"T. D. Keenan , Geographic atrophy in age-related macular degeneration: a tale of two stages. Ophthalmol. Sci. 3, 100306 (2023).","DOI":"10.1016\/j.xops.2023.100306"},{"key":"2026101005201191000_2026.09.19.26363031v2.11","doi-asserted-by":"publisher","DOI":"10.1038\/nrm2639"},{"key":"2026101005201191000_2026.09.19.26363031v2.12","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2016.278"},{"key":"2026101005201191000_2026.09.19.26363031v2.13","doi-asserted-by":"publisher","DOI":"10.1126\/science.277.5322.55"},{"key":"2026101005201191000_2026.09.19.26363031v2.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2024.02.014"},{"key":"2026101005201191000_2026.09.19.26363031v2.15","unstructured":"N. I. Mojumder , A. M. Khanani , The mechanism of the bispecific antibody faricimab. Retinal Physician (1 March 2019); article online (accessed 1 October 2026)."},{"key":"2026101005201191000_2026.09.19.26363031v2.16","doi-asserted-by":"publisher","DOI":"10.1172\/JCI89963"},{"key":"2026101005201191000_2026.09.19.26363031v2.17","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.01472-08"},{"key":"2026101005201191000_2026.09.19.26363031v2.18","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aai8030"},{"key":"2026101005201191000_2026.09.19.26363031v2.19","doi-asserted-by":"crossref","unstructured":"R. Lima e Silva , A. C. Mirando , S. Y. Tzeng , J. J. Green , A. S. Popel , N. B. Pandey , P. A. Campochiaro , Anti-angiogenic collagen IV-derived peptide target engagement with \u03b1v\u03b23 and \u03b15\u03b21 in ocular neovascularization models. iScience 26, 106078 (2023).","DOI":"10.1016\/j.isci.2023.106078"},{"key":"2026101005201191000_2026.09.19.26363031v2.20","doi-asserted-by":"crossref","first-page":"e122043","DOI":"10.1172\/jci.insight.122043","article-title":"A collagen IV\u2013derived peptide disrupts \u03b15\u03b21 integrin and potentiates Ang2\/Tie2 signaling","volume":"4","year":"2019","journal-title":"JCI Insight"},{"key":"2026101005201191000_2026.09.19.26363031v2.21","doi-asserted-by":"crossref","first-page":"5142","DOI":"10.3390\/ijms21145142","article-title":"Suppression of ocular vascular inflammation through peptide-mediated activation of angiopoietin-Tie2 signaling","volume":"21","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"2026101005201191000_2026.09.19.26363031v2.22","doi-asserted-by":"publisher","DOI":"10.64898\/2026.06.30.735614"},{"key":"2026101005201191000_2026.09.19.26363031v2.23","unstructured":"AsclepiX Therapeutics, Inc., Safety and Bioactivity of AXT107 in Subjects With Diabetic Macular Edema (CONGO). ClinicalTrials.gov, NCT04697758; https:\/\/clinicaltrials.gov\/study\/NCT04697758."},{"key":"2026101005201191000_2026.09.19.26363031v2.24","unstructured":"AsclepiX Therapeutics, Inc., Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration (SHASTA). ClinicalTrials.gov, NCT04746963; https:\/\/clinicaltrials.gov\/study\/NCT04746963."}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.64898\/2026.09.19.26363031","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T12:20:17Z","timestamp":1791634817000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.64898\/2026.09.19.26363031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,24]]},"references-count":24,"URL":"https:\/\/doi.org\/10.64898\/2026.09.19.26363031","relation":{},"subject":[],"published":{"date-parts":[[2026,9,24]]},"subtype":"preprint"}}